Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Portfolio Pulse from Vandana Singh
Italy's antitrust regulator is investigating Novartis AG and Roche Holdings AG-controlled Genentech for allegedly restricting competition in the sale of an eye drug, Byooviz. The probe focuses on potential delays in the Italian market launch of Byooviz, a biosimilar of Lucentis, due to coordinated strategies by these companies. The investigation could impact drug availability and prices for patients.
June 06, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novartis AG is under investigation by Italy's antitrust regulator for allegedly restricting competition in the sale of Byooviz, a biosimilar eye drug. The probe could impact drug availability and prices, potentially affecting Novartis' market position and financial performance.
The investigation could lead to legal and financial repercussions for Novartis, potentially affecting its market position and stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Roche Holdings AG-controlled Genentech is being investigated by Italy's antitrust regulator for allegedly restricting competition in the sale of Byooviz. The outcome of the investigation could affect Roche's market position and financial performance.
The investigation could lead to legal and financial repercussions for Roche, potentially affecting its market position and stock price negatively in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80